Literature DB >> 321222

Bromopyruvate as an affinity label for baker's yeast flavocytochrome b2. Kinetic study of the inactivation reaction.

C Mulet, F Lederer.   

Abstract

Bromopyruvate was shown to completely inactivate cytochrome b2 in a reaction that obeyed the kinetic criteria required for affinity labels: it inactivated flavocytochrome b2 according to saturation kinetics, and the inactivation reaction was competitively inhibited by the substrate or competitive inhibitors. Inactivation was irreversible. The behaviour of both forms of flavocytochrome b2 (lintact and proteolytically cleaved) was examined. It was found that the reduced cleaved enzyme was not inactivated by bromopyruvate; this phenomenon can probably be ascribed to a structural change undergone upon reduction. The value of the lactate dissociation constant of intact cytochrome b2 cytochrome b2 was determined in competition experiments with bromopyruvate. By comparison with the divergent published values for the Ks of the cleaved from, it appears that only those that differ from the Km by a factor of two or three are reasonable. This study opens the way for the identification of an active site residue and localization in the peptide chain of the bifunctional enzyme.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 321222     DOI: 10.1111/j.1432-1033.1977.tb11336.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  5 in total

1.  3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects.

Authors:  S M El Sayed; R M Abou El-Magd; Y Shishido; S P Chung; T H Diem; T Sakai; H Watanabe; S Kagami; K Fukui
Journal:  J Bioenerg Biomembr       Date:  2012-02-09       Impact factor: 2.945

2.  The carbanion of nitroethane is an inhibitor of, and not a substrate for, flavocytochrome b2 [L-(+)-lactate dehydrogenase].

Authors:  R Genet; F Lederer
Journal:  Biochem J       Date:  1990-02-15       Impact factor: 3.857

3.  Effect of 3-bromopyruvate acid on the redox equilibrium in non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells.

Authors:  Ewa Kwiatkowska; Martyna Wojtala; Agnieszka Gajewska; Mirosław Soszyński; Grzegorz Bartosz; Izabela Sadowska-Bartosz
Journal:  J Bioenerg Biomembr       Date:  2015-12-29       Impact factor: 2.945

Review 4.  Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: a concise literature review and case study.

Authors:  Salah Mohamed El Sayed; Walaa Gamal Mohamed; Minnat-Allah Hassan Seddik; Al-Shimaa Ahmed Ahmed; Asmaa Gamal Mahmoud; Wael Hassan Amer; Manal Mohamed Helmy Nabo; Ahmed Roshdi Hamed; Nagwa Sayed Ahmed; Ali Abdel-Rahman Abd-Allah
Journal:  Chin J Cancer       Date:  2014-03-14

5.  The Anticancer Drug 3-Bromopyruvate Induces DNA Damage Potentially Through Reactive Oxygen Species in Yeast and in Human Cancer Cells.

Authors:  Magdalena Cal; Irwin Matyjaszczyk; Ireneusz Litwin; Daria Augustyniak; Rafał Ogórek; Young Ko; Stanisław Ułaszewski
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.